Tina M. Woo

Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).

S. Demo, M. Aujay, T. Muchamuel, 2009, Journal of medicinal chemistry.

Multicenter Phase I Studies To Evaluate the Safety, Tolerability, and Clinical Response to Intensive Dosing with the Proteasome Inhibitor PR-171 in Patients with Relapsed or Refractory Hematological Malignancies.

S. Trudel, R. Orlowski, O. O’Connor, 2006 .

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.

S. Demo, M. Aujay, M. Bennett, 2007, Cancer research.

Phase 1b Evaluation of the Safety and Efficacy of a 30-Minute IV Infusion of Carfilzomib In Patients with Relapsed and/or Refractory Multiple Myeloma

E. Sausville, D. Siegel, S. Singhal, 2010 .

Potent Inhibition of Multiple Proteasome Subunits by Carfilzomib in Multiple Myeloma and Solid Tumor Patients

S. Arastu‐Kapur, C. Kirk, T. Renau, 2011 .